G0S2 mRNA expression was unchanged in CML patients following 7 days of in vivo imatinib therapy (GDS3518, Figure 1G)39 or when CML CD34+ cells were cultured ex vivo in the presence of imatinib (Figure 1H). The gene discussed is G0S2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.